Lung Cancer

Drug-related pneumonitis occurred among 18% of patients receiving osimertinib for advanced epidermal growth factor receptor mutation-positive non-small cell lung cancer, according to study results published in CHEST.

Since 1991, the rate of cancer mortality has declined by 33% in the United States, which translates to an estimated 3.8 million fewer cancer deaths over the past 30 years, according to a report from the American Cancer Society.

Healio will present its second annual Disruptive Innovators Awards for oncology/hematology this spring.

Although use of limited resection or stereotactic body radiation therapy for early-stage non-small cell lung cancer had comparable odds for at least one adverse event, the overall toxicity profiles differed, according to study results.

A preoperative biopsy procedure did not raise the risk for tumor spread through airspaces among patients with resected stage I non-small cell lung cancer, according to a study published in CHEST.

The addition of tumor treating fields to standard therapies significantly improved OS for certain patients with non-small cell lung cancer, according to the therapy’s manufacturer.

Earlier in the week, I was contacted by Ellen Dran, mother of the late Dr. Sarah Hallberg. For those who may not know her, Sarah was a champion of medicine and of life.

A novel anti-TIGIT antibody improved overall response rates and extended PFS when added to anti-PD-1 therapy and to anti-PD-1 therapy plus an adenosine receptor antagonist for patients with advanced, PD-L1-high non-small cell lung cancer.

Implementation of lung cancer screening across five diverse health care systems led to higher rates of stage I diagnoses and lower rates of stage IV disease, study results showed.